Connect Biopharma is trading 5.6% down at $2.51 today, likely reflecting profit-taking and consolidation following a sharp 19.8% gain on July 9.
- The stock recently saw bullish momentum after Oppenheimer initiated coverage with an Outperform rating and an $8 price target, with other analysts setting targets between $4 and $10.
- The company also reached a clinical milestone by completing enrollment in its Phase 2 Seabreeze STAT Asthma study.
- Today's move appears to be stock-specific as the broader market remains relatively flat.